Summary:
A 15 month clinical research study is evaluating if a new investigational basal insulin dosed once daily can provide safe and effective blood sugar control compared to a marketed basal insulin dosed once daily in people with type 2 diabetes.
Qualified Participants Must:
• Be 18 years of age, or older
•
Have had a diagnosis of type 2 diabetes for at least 6 months
•
Be receiving treatment with any basal insulin with or without oral anti-diabetic drugs for at least 6 months
•
Be at high risk for developing hypoglycaemia (ie. recent hypoglycaemic episode, severe hypoglycaemic episode, hypoglycaemic unawareness, moderate chronic renal failure or insulin usage for more than 5 years)
•
Have an HbA1c level of not more than 9.5%
•
Have a body mass index (BMI) of less than 45 kg/m
Qualified Participants May Receive:
$50 per visit compensation for time and travel expenses.